Clinical Trial Update: Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating HARVONI for hepatitis C virus-associated indolent B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent B-cell Lymphoma

Drugs mentioned

• HARVONI (Ledipasvir and Sofosbuvir)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Indolent Lymphoma | Phase 2 | Status: UNKNOWN